Orientbio오리엔트바이오

Orientbio's shares have fallen sharply over the past year while losses have widened, with the business still loss-making on the latest trailing numbers.

Orientbio supplies laboratory animals and related biological materials for drug development, and also makes medical and laboratory equipment. On trailing figures to Q1 2026 it had revenue of about ₩28.3B, an operating loss of ₩1.4B and a net loss of ₩6.3B, with cash of ₩11.0B and very little borrowing. The share price closed at ₩1,476 on 20 October 2026, down 40.5% over one year.

What stands out

• Revenue has been roughly flat at about ₩25B to ₩29B across 2021 to 2025, but operating and net results have swung between profit and loss; 2025 showed a net loss of ₩13.2B.
• 2024 net income of ₩12.9B was positive, but the data does not explain what drove it, and it sits against losses in most other years.
• Valuation metrics are mixed: price-to-book is about 0.6 and price-to-sales about 1.5, while P/E is not meaningful because earnings are negative. The fair value model gives a base estimate of ₩79 and a bear case of ₩277, far below the current price; the model's bull value is shown as 0, which looks like a data gap.
• Foreign ownership fell from 0.2% to 0% over the last 60 days, while retail investors were net sellers over the past 20 days.
• Recent filings are mostly routine: shareholder meeting results, insider shareholding reports and a quarterly report for June 2026. No recent news headlines are included in the data.

What to watch

• The next quarterly or annual results, to see whether operating losses narrow from the trailing figures.
• Further 5%+ holding and insider shareholding reports, which may show changes in major ownership.
• Free cash flow was negative at about ₩-0.4B on a trailing basis; the data does not say how long cash of ₩11.0B would cover losses at this pace.